Status:
COMPLETED
Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients
Lead Sponsor:
Centre Hospitalier Universitaire de Besancon
Conditions:
HER2-positive Gastric Cancer
Metastatic Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this retrospective study is to evaluate the efficacy and the safety of trastuzumab + chemotherapies with or without taxanes among HER2-positive advanced gastroesophageal adenocarcinoma ...
Detailed Description
Studies have reported a beneficial role of trastuzumab combined to platin-5-FU based chemotherapy in first-line advanced HER2 positive gastroesophageal adenocarcinoma. However, the effect of taxanes c...
Eligibility Criteria
Inclusion
- histologically confirmed non-resectable locally advanced, recurrent, or metastatic adenocarcinoma of the stomach or gastro-esophageal junction;
- tumor samples scored as 3+ on immunohistochemistry or FISH (Fluorescence in situ Hybridization) positive (HER2:CEP17 ratio ≥2);
- measurable disease;
- treated by trastuzumab, platin (cisplatine or oxaliplatine), fluoropyrimidine (5-FU or capecitabine) +/- taxanes (docetaxel or paclitaxel),
- as first-line therapy for advanced gastric cancer.
Exclusion
- previous chemotherapy by taxane for metastatic disease,
- previous anti-HER2 therapy.
Key Trial Info
Start Date :
April 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 31 2021
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT04920747
Start Date
April 1 2021
End Date
May 31 2021
Last Update
June 10 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Besancon
Besançon, Franche-Comté, France, 25030